前药
乳腺癌
医学
癌症
多西紫杉醇
癌症研究
癌症干细胞
药品
肿瘤科
癌细胞
盐霉素
内科学
化疗
毒性
纳米医学
CA15-3号
药理学
癌症治疗
干细胞
转移性乳腺癌
肿瘤细胞
治疗方式
人体乳房
癌症治疗
MCF-7型
作者
Tongyao Zhao,Yue Chen,Haimeng Yuan,S. Yang,H. Zhang,Yuequan Wang,Shenwu Zhang,Qin Chen,Jie Sun,Zhonggui He,Cong Luo
摘要
ABSTRACT Cancer stem cells (CSCs) are widely recognized as the culprits of chemoresistance, tumor metastasis, and relapse. Moreover, most chemotherapeutic drugs not only fail to eliminate CSCs effectively, but also induce the acquisition of stemness characteristics in non‐stem cancer cells. Herein, we propose a cancer cells/CSCs double‐killing modality for breast cancer treatment. Specifically, a carrier‐free nano‐cocktail is developed through the precise co‐assembly of a redox‐responsive docetaxel (DTX) dimeric prodrug and salinomycin (SAL, an anti‐CSCs drug). Precision combination of DTX and SAL not only shows synergistic tumor‐killing activity, but also sharply reduces the proportion of CSCs in tumors. More importantly, tumor‐specific prodrug activation‐initiated drug release from the nano‐cocktail confers high drug co‐delivery efficiency and low off‐target toxicity risk. As expected, such a one‐stone‐two‐birds nanomedicine presents satisfactory performance on tumor stemness eradication, antitumor responses, and safety in both xenograft and orthotopic 4T1 breast cancer mouse models. This study advances cancer cells/CSCs double‐killing nanotherapeutics towards clinical breast cancer therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI